中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(3): 527-532

Effect of human umbilical cord mesenchymal stem cells in treatment of mice with liver fibrosis and its mechanism

DOI: 10.12449/JCH240315

  • Department of Infectious Diseases，Renmin Hospital of Wuhan University，Wuhan 430060，China

Research funding:

The Grant From the Anti-Aging Research Center, Wuhan University Education & Development Foundation (2002330);

The Fundamental Research Funds for the Central Universities (2042022kf1115)

More Information
  • Corresponding author: JIANG Yingan， jiangya_cn@aliyun.com （ORCID： 0000-0003-4912-7494）
  • Received Date: 2023-06-09
  • Accepted Date: 2023-08-17
  • Published Date: 2024-03-20
    Abstract
  •   Objective  To investigate the effect of human umbilical cord mesenchymal stem cells （hUCMSCs） in the treatment of mice with liver fibrosis and its mechanism.  Methods  A total of 18 specific pathogen-free C57BL/6 mice， aged 6 weeks， were selected and divided into control group （n=6）， carbon tetrachloride （CCl4） model group （CCl4 group， n=6）， and hUCMSCs treatment group （MSC group， n=6） using a random number table. The mice in the CCl4 group and the MSC group were given intraperitoneal injection of CCl4 solution to establish a mouse model of liver fibrosis， while those in the control group were injected with the same dose of corn oil， and the mice in the MSC group were injected with hUCMSCs via the caudal vein during the injection of CCl4. At the end of week 8， mouse serum was collected， and the mice were sacrificed to collect and fix the liver. Enzyme-linked immunosorbent assay was used to measure the levels of inflammatory factors； an automatic biochemical detector was used to measure liver function parameters； HE staining， Masson staining， Sirius Red staining， and α-SMA immunofluorescence assay were used to evaluate liver fibrosis. Hepatic stellate cells （HSCs） stimulated by TGF-β were co-cultured with hUCMSCs in the medium with or without chitinase-3 like-protein-1 （CHI3L1）， and Western blot was used to measure the expression levels of proteins. A one-way analysis of variance was used for comparison of continuous data between multiple groups， and the Dunnett’s t-test was used for further comparison between two groups.  Results  Masson staining and Sirius Red staining showed that the CCl4 group had a significantly higher degree of fibrosis than the control group （both P<0.05）， and the MSC group had significant alleviation of fibrosis compared with the CCl4 group （both P<0.05）. Compared with the control group， the CCl4 group had significant increases in the levels of interleukin-1β， interleukin-6 （IL-6）， aspartate aminotransferase （AST）， alanine aminotransferase （ALT）， and alkaline phosphatase （ALP） （all P<0.05）， and compared with the CCl4 group， the MSC group had significant reductions in the levels of IL-6， AST， ALT， and ALP （all P<0.05）. The CCl4 group had significantly higher expression levels of CHI3L1 and α-SMA than the control group and the MSC group （all P<0.05）. The cell culture experiment showed that the MSC+HSC group had a significantly higher expression level of Bax than the HSC group and the MSC+CHI3L1 group （both P<0.05）， suggesting that CHI3L1 reversed the pro-apoptotic effect of MSC on activated HSCs.  Conclusion  This study shows that hUCMSCs can improve liver fibrosis in mice， possibly by inhibiting CHI3L1 to promote the apoptosis of HSCs.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    TORRES S, ORTIZ C, BACHTLER N, et al. Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis[J]. Hepatology, 2023, 77( 4): 1228- 1240. DOI: 10.1002/hep.32746.
    [2]
    LI S, ZHOU B, XUE M, et al. Macrophage-specific FGF12 promotes liver fibrosis progression in mice[J]. Hepatology, 2023, 77( 3): 816- 833. DOI: 10.1002/hep.32640.
    [3]
    XIA SL, LIU ZM, CAI JR, et al. Liver fibrosis therapy based on biomimetic nanoparticles which deplete activated hepatic stellate cells[J]. J Control Release, 2023, 355: 54- 67. DOI: 10.1016/j.jconrel.2023.01.052.
    [4]
    LIU YW, DONG YT, WU XJ, et al. The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: A systematic review and meta-analysis of randomized controlled clinical trials[J]. Stem Cell Res Ther, 2022, 13( 1): 204. DOI: 10.1186/s13287-022-02882-4.
    [5]
    ZHANG ZL, SHANG J, YANG QY, et al. Exosomes derived from human adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline metabolism[J]. J Nanobiotechnology, 2023, 21( 1): 29. DOI: 10.1186/s12951-023-01788-4.
    [6]
    ZHAO T, SU ZP, LI YC, et al. Chitinase-3 like-protein-1 function and its role in diseases[J]. Signal Transduct Target Ther, 2020, 5( 1): 201. DOI: 10.1038/s41392-020-00303-7.
    [7]
    YANG H, ZHAO LL, HAN P, et al. Value of serum chitinase-3-like protein 1 in predicting the risk of decompensation events in patients with liver cirrhosis[J]. J Clin Hepatol, 2023, 39( 7): 1578- 1585. DOI: 10.3969/j.issn.1001-5256.2023.07.011.

    杨航, 赵黎莉, 韩萍, 等. 血清壳多糖酶3样蛋白1(CHI3L1)对肝硬化患者发生失代偿事件风险的预测价值[J]. 临床肝胆病杂志, 2023, 39( 7): 1578- 1585. DOI: 10.3969/j.issn.1001-5256.2023.07.011.
    [8]
    MA L, WEI J, ZENG Y, et al. Mesenchymal stem cell-originated exosomal circDIDO1 suppresses hepatic stellate cell activation by miR-141-3p/PTEN/AKT pathway in human liver fibrosis[J]. Drug Deliv, 2022, 29( 1): 440- 453. DOI: 10.1080/10717544.2022.2030428.
    [9]
    NISHIMURA N, DE BATTISTA D, MCGIVERN DR, et al. Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis[J]. Proc Natl Acad Sci U S A, 2021, 118( 17): e2019633118. DOI: 10.1073/pnas.2019633118.
    [10]
    WANG CG, LI SZ, SHI JM, et al. Research progress in differentiation, identification, and purification methods of human pluripotent stem cells to mesenchymal-like cells in vitro[J]. J Jilin Univ Med Ed, 2023, 49( 6): 1655- 1661. DOI: 10.13481/j.1671-587X.20230634.

    王成刚, 李生振, 史嘉敏, 等. 体外人多能干细胞向间充质样细胞分化、鉴定和纯化方法的研究进展[J]. 吉林大学学报(医学版), 2023, 49( 6): 1655- 1661. DOI: 10.13481/j.1671-587X.20230634.
    [11]
    LI TT, WANG ZR, YAO WQ, et al. Stem cell therapies for chronic liver diseases: Progress and challenges[J]. Stem Cells Transl Med, 2022, 11( 9): 900- 911. DOI: 10.1093/stcltm/szac053.
    [12]
    YANG X, LI Q, LIU WT, et al. Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: From pathogenesis to treatment[J]. Cell Mol Immunol, 2023, 20( 6): 583- 599. DOI: 10.1038/s41423-023-00983-5.
    [13]
    ZHAO SX, LIU Y, PU ZH. Bone marrow mesenchymal stem cell-derived exosomes attenuate D-GaIN/LPS-induced hepatocyte apoptosis by activating autophagy in vitro[J]. Drug Des Devel Ther, 2019, 13: 2887- 2897. DOI: 10.2147/DDDT.S220190.
    [14]
    LEE CG, HARTL D, LEE GR, et al. Role of breast regression protein 39(BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis[J]. J Exp Med, 2009, 206( 5): 1149- 1166. DOI: 10.1084/jem.20081271.
    [15]
    HIGASHIYAMA M, TOMITA K, SUGIHARA N, et al. Chitinase 3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis[J]. Hepatol Res, 2019, 49( 11): 1316- 1328. DOI: 10.1111/hepr.13396.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (301) PDF downloads(50) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return